Sanofi unveils heart disease partnership with MyoKardia
By Reuters
Sep 17, 2014 03:23 AM EDT
Regions
This Reuters photo shows an employee walking into an office of French drugmaker Sanofi in Shanghai. (Photo : Reuters)
French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.
The collaboration includes up to $200 million in equity investments, milestone payments, and research and development services through 2018, Sanofi said in a statement.
MyoKardia was founded in 2012 and is funded by healthcare investor Third Rock Ventures.
© Reuters All rights reserved.